Annette Komlo
Data Coordinator 2
Research & Publications
Biography
Coauthors
Selected Publications
- Nivolumab and ipilimumab in advanced non small cell lung cancer previously treated with PD1 axis inhibition.Gettinger S, Wilson F, Goldberg S, Chiang A, Henick B, Rowen E, Gerrish H, Duffield E, Davies M, Dest V, Komlo A, Pope J, Cheng W, Schalper K, Herbst R. Nivolumab and ipilimumab in advanced non small cell lung cancer previously treated with PD1 axis inhibition. Journal Of Clinical Oncology 2023, 41: 9121-9121. DOI: 10.1200/jco.2023.41.16_suppl.9121.
- Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trialGoldberg SB, Schalper KA, Gettinger SN, Mahajan A, Herbst RS, Chiang AC, Lilenbaum R, Wilson FH, Omay SB, Yu JB, Jilaveanu L, Tran T, Pavlik K, Rowen E, Gerrish H, Komlo A, Gupta R, Wyatt H, Ribeiro M, Kluger Y, Zhou G, Wei W, Chiang VL, Kluger HM. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. The Lancet Oncology 2020, 21: 655-663. PMID: 32251621, PMCID: PMC7380514, DOI: 10.1016/s1470-2045(20)30111-x.
- Durability of brain metastasis response and overall survival in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab.Goldberg S, Gettinger S, Mahajan A, Herbst R, Chiang A, Lilenbaum R, Jilaveanu L, Rowen E, Gerrish H, Komlo A, Wei W, Chiang V, Kluger H. Durability of brain metastasis response and overall survival in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab. Journal Of Clinical Oncology 2018, 36: 2009-2009. DOI: 10.1200/jco.2018.36.15_suppl.2009.